ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Small Cell Lung Carcinoma
Cancer
Colorectal Cancer
Neoplasm Metastasis
Breast Cancer
Squamous Cell Carcinoma of Head and Neck

Lung Cancer trials near Birmingham, AL, USA:

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCL...

Enrolling
Small Cell Lung Cancer
Non-Small Cell Lung
Drug: AL8326 40 mg
Drug: AL8326 60 mg

Phase 2

Advenchen

Birmingham, Alabama, United States and 6 other locations

Study With Various Immunotherapy Treatments in Participants With Lung Cancer (EDGE-Lung)

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Active, not recruiting
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Zimberelimab

Phase 2

Gilead Sciences
Gilead Sciences

Birmingham, Alabama, United States and 52 other locations

Locations recently updated

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung...

Enrolling
Carcinoma Non Small Cell Lung
Advanced Non Small Cell Lung Cancer
Drug: Sarilumab
Drug: Marlotamig

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Birmingham, Alabama, United States and 16 other locations

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...

Enrolling
Extensive Stage-small Cell Lung Cancer
Drug: Carboplatin
Drug: Ifinatamab deruxtecan

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Birmingham, Alabama, United States and 58 other locations

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)

The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by inves...

Active, not recruiting
Relapsed/Refractory Small Cell Lung Cancer
Drug: Tarlatamab

Phase 2

Amgen
Amgen

Birmingham, Alabama, United States and 80 other locations

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sit...

Enrolling
Small Cell Lung Cancer
Drug: Topotecan
Drug: Lurbinectedin

Phase 3

AbbVie
AbbVie

Birmingham, Alabama, United States and 71 other locations

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Lung Carcinoma
Drug: Pembrolizumab
Drug: BBO-10203

Phase 1

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Birmingham, Alabama, United States and 37 other locations

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer...

Enrolling
HR+/HER2- Ductal and Lobular Breast Cancer
Non-small Cell Lung Cancer
Drug: [68Ga]Ga-NNS309
Drug: [177Lu]Lu-NNS309

Phase 1

Novartis
Novartis

Birmingham, Alabama, United States and 28 other locations

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung...

Active, not recruiting
Small Cell Lung Carcinoma Extensive Disease
Drug: Carboplatin
Drug: Tremelimumab

Phase 3

AstraZeneca
AstraZeneca

Birmingham, Alabama, United States and 206 other locations

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung...

Active, not recruiting
Advanced Non-Small Cell Squamous Lung Cancer
Advanced Lung Carcinoma
Drug: silevertinib (BDTX-1535) monotherapy

Phase 1, Phase 2

Black Diamond Therapeutics

Birmingham, Alabama, United States and 28 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems